ABSTRACT PURPOSE: To compare matched populations of LASIK and Visian Implantable Collamer Lens (ICL) cases in the correction of myopia between Ϫ3.00 and Ϫ7.88 diopters (D).
RESULTS: At 6 months, best spectacle-corrected visual acuity (BSCVA) у20/20 was 85% with LASIK and 95% with ICL (P=.003) compared to preoperative values of 93% and 88%, respectively (P=.292). Loss of у2 lines of BSCVA was signifi cantly lower with the ICL at 1 week (0.6% vs 10%, PϽ.001) and 1 month (7% vs 0%, P=.001) with comparable outcomes at 6 months (0% vs 1%). At 6 months postoperatively, uncorrected visual acuity (UCVA) у20/15 (11% vs 25%, P=.001) and у20/20 (49% vs 63%, P=.001) was better in the ICL cases. Predictability within 0.50 D at 6 months for ICL cases was 85% (67% LASIK, PϽ.001); 97% of ICL cases were within 1.00 D (88% LASIK, P=.002). Refractive stability (Ϯ0.50 D) between 1 and 6 months was 93% with ICL compared to only 82% with LASIK (P=.006).
CONCLUSIONS:
The ICL performed better than LASIK in almost all measures of safety, effi cacy, predictability, and stability in this matched population comparison, supporting the ICL as an effective alternative to existing refractive laser surgical treatments for the range of myopia studied. [J Refract Surg. 2007; 23:537-553.] A previous report of the multicenter United States Food and Drug Administration (US FDA) Visian Myopic Implantable Collamer Lens (Visian ICL; STAAR Surgical, Monrovia, Calif) clinical investigation has documented the safety and effectiveness of the Visian ICL in the correction of low, moderate, and high levels of myopia with follow-up out to 3 years. 1, 2 Outcomes from this large multicenter clinical study have demonstrated the viability of the Visian ICL as an alternative to current refractive laser surgical treatment options. In December 2005, the FDA approved the Visian ICL for myopia Ϫ3.00 to Ϫ20.00 diopters (D).
This article presents a comparison of clinical outcomes with the current commercially approved version of the Visian ICL with LASIK for the correction of myopia at the lower range for which the ICL is being considered for approval (Ϫ3.00 to Ϫ7.88 D). The overall study populations have been matched for age, gender, and mean preoperative manifest refraction spherical equivalent (MRSE) to provide a comparison of these two refractive surgical techniques.
PATIENTS AND METHODS
A matched patient population evaluation was performed involving 164 LASIK eyes (136 patients) from the Davis Duehr
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Eye Center, Madison, Wisconsin and 164 ICL eyes (106 patients) from the multicenter US FDA Clinical Trial for ICL for Myopia. Implantable Collamer Lens implantations occurred between November 1998 and September 2000; LASIK surgeries were performed from May 2001 to June 2002. In both groups, preoperative MRSE ranged between Ϫ3.00 and Ϫ7.88 D, and study follow-up was 1 day, 1 week, 1 month, and 6 months postoperatively. All LASIK cases were conducted at a single center by 9 surgeons. Implantable Collamer Lens surgeries were performed at 12 centers by 16 surgeons. Implantable Collamer Lens cases were conducted under the supervision of an institutional review board at all participating centers and written surgical informed consent was obtained for all ICL and LASIK patients prior to surgery.
The 164 ICL case series included a consecutive series of all ICL cases in the US FDA trial for this range of myopia. The LASIK series was drawn from a consecutive series of 2577 cases for this range of myopia during the enrollment period described above. This enrollment period was chosen because extensive follow-up data were available as part of a prospective data collection of all cases at the center. The computerized database of all LASIK cases was discontinued shortly after this period. An attempt was made to match each case in the ICL population with a case in the LASIK population of similar age, gender, and spherical equivalent refraction without knowledge of postoperative outcomes. If more than one LASIK case adequately matched an ICL case, preference was given to the case with у6-month follow-up. If more than one case matched that had у6-month follow-up, the fi rst such case encountered was used. If an exact match could not be made for all three variables (age, gender, and spherical equivalent refraction), a correction was attempted in a later case to maintain a matched population set. All refraction data in both series were obtained by manifest refraction without cycloplegia.
The LASIK and ICL study populations were well matched for age (LASIK: 37.3Ϯ7 years; ICL: 37 
VISIAN ICL DEVICE
The current Visian ICL was implanted in all eyes in the phakic intraocular lens (IOL) arm of the series. The ICL confi guration was designed to vault anteriorly to the crystalline lens and is intended to have minimal contact with the natural lens. As discussed previously by the authors, the lens is made from a new generation of biocompatible IOL materials, termed "Collamer." [1] [2] [3] [4] It is composed of a proprietary hydrophilic porcine collagen (Ͻ0.1%) hydroxyethyl methacrylate (HEMA) copolymer into which an ultraviolet-absorbing chromophore has been incorporated in the polymer chains. The ICL features an optic with an overall diameter that varies with its dioptric power, with the smallest optic/overall diameter being 4.9 mm/12.1 mm and the largest being 5.8 mm/13.7 mm. Its plate-haptic design resembles lenses already in use with cataract surgery; it also incorporates four separate, distinct extensions of the haptics referred to as footplates.
LASIK EQUIPMENT
All 164 eyes underwent LASIK using a current LASIK technique performed with the same microkeratome design. Three manual microkeratomes (CarriazoBaraquer; Moria, Antony, France), all with a 160-µm head, were used to perform the fl ap creation in all eyes by the LASIK surgeon group for these cases. The STAR 193 nanometer excimer laser system (VISX Inc, Santa Clara, Calif) incorporating the S3 software version was the laser used to perform all ablations.
LENS SIZING AND POWER CALCULATION
Sizing of myopic lenses (12.2 to 13.7 mm) was determined by the horizontal white-to-white and the anterior chamber depth measurements. For eyes with anterior chamber depth measurements of 2.8 to 3.5 mm, the lens size was calculated by adding 0.5 mm to the horizontal white-to-white measurement. Eyes exhibiting an anterior chamber depth Ͼ3.5 mm required the addition of up to 1.0 mm to the white-to-white measurement, up to a maximum length of 13.7 mm. Patients with an anterior chamber depth Ͻ2.8 mm were excluded from the study. Calculated lens sizes between the available lens diameters (in 0.5-mm increments) were generally rounded down if the anterior chamber depth was р3.5 mm and rounded up if the anterior chamber depth was Ͼ3.5 mm. White-to-white measurements were obtained using calipers at a slit lamp checked against a steel ruler. All lens power calculations were performed by STAAR Surgical Company using a clinically optimized vergence formula that was based upon paraxial optics and vergence equations. The formula was recently enhanced to allow for toric as well as spherical calculations, 5 and this formula was utilized using an effective lens position (elp) value of 3.64. The refractive target was between 0 and Ϫ0.50 D in all cases.
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ICL SURGICAL PROCEDURE
Within 7 days of surgery, patients received two peripheral iridectomies performed 90° apart with an Nd:YAG or Argon-Krypton laser, generally at 10:30 and 1:30 clock hours. On the day of surgery, patients were administered dilating and cycloplegic agents, after which an anesthetic of the surgeon's choice was applied to the operative eye. All ICL implantations were performed under topical anesthesia. Following placement of viscoelastic into the anterior chamber, an ICL was inserted through a small 3-mm horizontal (0 to 180°) clear corneal incision. The lens was injected through the incision into the anterior chamber (STAAR MicroSTAAR injector) and allowed to slowly unfold. Distal and proximal footplates were tucked under the iris with a modifi ed intraocular spatula. Correct positioning of the ICL in the center of the pupillary zone was verifi ed before intraocular miotic was used to decrease pupil size. Any remaining viscoelastic was scrupulously irrigated out of the anterior chamber with balanced salt solution (BSS).
Patients were administered one drop of Ocufl ox (ofl oxacin solution 0.3%; Allergan Inc, Irvine, Calif) and prescribed Tobradex (tobramycin and dexamethasone suspension; Alcon Laboratories Inc, Ft Worth, Tex) four times daily for a total of 16 days, beginning with one drop four times daily for the fi rst four postoperative days and steadily reducing the dose by one drop every four days thereafter. No postoperative medication was routinely used after this time frame.
No operative or postoperative procedures were permitted for the treatment of residual spherical or astigmatic refractive error.
LASIK SURGICAL TECHNIQUE
Topical 0.5% proparacaine, three to six drops, was applied immediately prior to surgery. Orientation marks were placed on the cornea with gentian violet to facilitate repositioning of the fl ap. Average attempted corneal fl ap diameter was 8.5 mm with a superior hinge position. All LASIK procedures were done using the VISX STAR excimer laser with the S3 software with a repetition rate of 6 or 10 Hz and an ablation zone diameter of 6.0 or 6.5 mm. During ablation, patients autofi xated on a target light and centration was achieved by the surgeon using an aiming reticule centered on the pupil. Following ablation, the corneal fl ap was repositioned using a 27-gauge blunt cannula with BSS (Alcon Laboratories Inc). The fl ap position was confi rmed and the cornea air-dried for 3 minutes. At the completion of the procedure, one drop each of topical Ciloxan (Alcon Laboratories Inc) and prednisolone acetate (Alcon Laboratories Inc) were instilled and clear corneal shields were taped into position. In the event of epithelial abrasion, a bandage contact lens was applied at the surgeon's discretion.
Ciloxan and prednisolone acetate were prescribed four times daily and discontinued after 5 days. Patients were seen 1 day following surgery and typically at 1 day, 1 week, 1 month, and 6 months postoperatively.
Enhancement criteria were unique for each surgeon but in general the following criteria were adhered to by all participating surgeons. Enhancement was driven by patient desire, not by the level of visual acuity. Enhancements were performed when uncorrected visual acuity (UCVA) was Ͻ20/30 and there was suffi cient corneal bed thickness/structural corneal stability to allow re-treatment.
The original refractive target was between 0 and Ϫ0.50 D in all cases. Astigmatism was routinely treated as part of the surgical procedure.
STATISTICAL METHODS
Implantable Collamer Lens outcomes were compiled from the prospective, standardized case report forms in Clindex 2.0 (Fortress Medical Systems Inc, Hopkins, Minn) provided in the US multicenter clinical study protocol. For LASIK, outcomes reported in the clinical records were compiled on an Excel spreadsheet (Microsoft Corp, Redmond, Wash). If enhancements were performed, data after enhancement were included in the visual and refractive results.
The following statistical analyses were used to compare the LASIK and ICL series. For dichotomous variables (gender, BSCVA or UCVA 20/15, 20/20, and 20/40 or better, predictability Ϯ0.50 or Ϯ1.00 D, and stability Ϯ0.50 or Ϯ1.00 D), Fisher's exact test was performed. For ordered categories and interval level data (patient age, vision distributions, line changes in BSC-VA and spherical equivalent refraction, predictability, and stability refractive distributions) Mann-Whitney U tests were performed. SPSS 11.0 (SPSS Inc, Chicago, Ill) was used for all tabulations of data and statistics.
RESULTS
POSTOPERATIVE FOLLOW-UP
Implantable Collamer Lens and LASIK patients were examined at 1 day, 1 week, 1 month, and 6 months postoperatively. As part of the US ICL FDA multicenter clinical study, follow-up was excellent with 96% of eyes seen 6 months postoperatively. In the LASIK group, 99% of eyes were examined at 6-month follow-up. Table 1 provides an overall comparison of the major safety and effi cacy outcomes between the LASIK and ICL groups. The column labeled "P Value" for values that were dichotomous variables represents results of Fisher's exact tests. For these dichotomous variables the entire distribution of outcomes for that variable was also analyzed and signifi cance was determined by a MannWhitney U test. The results of this test are given in the last column labeled "P Value, Entire Distribution." Fig 1) . The differences were statistically signifi cant at all three postoperative follow-up examinations where BSCVA was measured: 1 week (88% vs 67%, PϽ.001), 1 month (97% vs 82%, PϽ.001), and 6 months (95% vs 85%, P=.003). Using the entire distribution of BSCVA values and not just a breakdown at 20/20, the ICL patients had better BSCVA at all postoperative visits between 1 week and 6 months (PϽ.001).
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CLINICAL OUTCOMES
Preservation of BSCVA was better with the ICL during the immediate healing period and through 6-month follow-up. Loss of у2 lines of BSCVA was signifi cantly higher in the LASIK series in the early healing period (1 week 10% vs 0.6%, PϽ.001) and at 1-month followup (7% vs 0%, PϽ.001) ( Table 1, Fig 2) . Improvement in BSCVA (у2 lines) was not statistically different between the two groups although the entire distribution of change in BSCVA was statistically better with the ICL at all follow-up examinations through 6 months (PϽ.001). 
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These differences between the two surgical procedure groups were also noted when comparing gains and losses of у1 line of BSCVA (Table 1) . Losses of у1 line of BSCVA were signifi cantly higher in the LASIK series at 1-week (31% vs 15%, P=.003), 1-month (19% vs 7%, P=.001), and 6-month follow-up (14% vs 5%, P=.006). Improvement of у1 line BSCVA was better with the ICL series at all time periods studied (Pр.001 at 1 week and 6 months; P=.001 at 1 month). At 6-month follow-up, 44% of patients had an improvement of у1 line of BSCVA in the ICL series at 6-month follow-up compared to 15% in the LASIK series. Figure 3 presents the entire distribution of BSCVA gains and losses at 6 months postoperatively demonstrating a shift of the cases to the right (toward more improvement in BSCVA) in the ICL series relative to the LASIK series.
The mean change in BSCVA was signifi cantly better with the Visian ICL than with LASIK at all time periods from 1 week through 6-month follow-up (Table 1, Fig 4) . Improvements were noted at 1 week postoperatively in the ICL series and reached approximately a ½ line gain at 6-month follow-up. The LASIK series showed an average loss of BSCVA at 1 week postoperatively, a minimal loss/no change at 1 month with essentially no change in BSCVA at 6 months postoperatively. At all time periods, the ICL group demonstrated signifi cantly more improvement in BSCVA than the LASIK group (PϽ.001).
SECONDARY SURGERIES/ADVERSE EVENTS
During the 6-month course of this study, one (0.6%) ICL was replaced within the fi rst postoperative week because the ICL was too long, and one (0.6%) ICL was repositioned twice due to two improper rotational placements of the ICL. Six (3.7%) eyes underwent an additional YAG iridotomy during the postoperative period usually due to acute pressure rises, which resolved after the YAG procedure, and one (0.6%) eye had a YAG procedure postoperatively that did not undergo one prior to ICL implantation. No (0.0%) ICL removals occurred during the course of the study. None of these events were associated with a signifi cant loss of BSCVA.
No anterior subcapsular crystalline lens opacities were noted. Furthermore, no cataract extractions were performed on any patient during the course of the study. No ICL cases were treated with LASIK or had an ICL replacement for improper refractive correction.
Re-treatments with the laser (enhancements) oc- 
EFFECTIVENESS OUTCOMES
Uncorrected visual acuity improved dramatically in both groups (Table 1 ). The proportion of cases seeing у20/15 was numerically higher in the ICL series at all postoperative time periods and was signifi cantly better at 6 months postoperatively (25% vs 11%, P=.001) (Fig 5) . The proportion of cases with UCVA у20/20 was signifi cantly higher in the ICL group at 1 month (59% vs 43%, P=.011) and 6 months postoperatively (63% vs 49%, P=.010) (Fig 6) . Although the proportion of cases with UCVA у20/40 was signifi cantly better in the LASIK series on the fi rst postoperative day (84% vs 70%, P=.004), the proportion of eyes with UCVA у20/40 was numerically higher in the ICL series at 1 week, 1 month, and 6 months but the differences were not statistically signifi cant. Using the entire distribution of UCVA values and not just the 20/15, 20/20, or 20/40 cutoffs, the ICL was signifi cantly better than LASIK at 1-month (P=.01) and 6-month (PϽ.001) follow-up.
Figures 7A and 7B provide comparisons of preoperative BSCVA to 6-month UCVA outcomes for the ICL and LASIK series, respectively. Uncorrected visual acuity appeared to approach BSCVA at better levels of visual acuity in the ICL series. Preoperatively, 88% of ICL patients saw 20/20 BSCVA and 63% saw 20/20 UCVA at 6 months postoperatively, a differential of 25%, whereas in the LASIK patients, 93% saw 20/20 BSCVA preoperatively and only 49% saw 20/20 UCVA at 6 months postoperatively, a differential of 44%. This differential also favored the ICL series at у20/25 (14% ICL vs 27% LASIK) and у20/30 (6% ICL vs 16% LASIK).
Predictability (attempted vs achieved correction) favored the ICL at all postoperative visits and was statistically better at 6 months postoperatively with regard to Ϯ0.50 D (LASIK 67%, ICL 85%; PϽ.001) and Ϯ1.00 D (LASIK 88%, ICL 97%; P=.002) ( Table  1) . Examination of the scattergrams demonstrates more variability in the LASIK group and a tendency to undercorrect especially for attempted corrections Ͼ6.00 D (Fig 8) .
Postoperative defocus equivalent refraction Ϯ0.50 D and Ϯ1.00 D tended to slightly favor the LASIK group; however, the differences were not statistically significant (Fig 9) .
Although signifi cantly more refractive cylinder was noted in the LASIK series preoperatively than in the ICL series (0.74 vs 0.58 D, P=.037), there was significantly less in the LASIK series at all postoperative visits (PϽ.001) ( Table 1) The stability of refraction (proportion of cases with р0.50-D change) was signifi cantly better in the ICL se- A B
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ries compared to the LASIK series through 6 months ( Table 1 ). The proportion of eyes with a р0.50-D change between 1 month and 6 months was 93% in the ICL series and 82% in the LASIK series (PϽ.006). The stability of refraction (proportion of cases with р1.00-D change) was excellent (у95%) in both groups (97% LASIK and 99% ICL) between 1 month and 6 months and was not statistically different. There was a statistically signifi cant advantage with the ICL with regard to р1.00-D change between 1 week and 1 month (92% LASIK, 99% ICL, P=.009).
The stability of refraction graphs over time demonstrated good refractive stability in both groups (Fig 10) . The postoperative spherical equivalent refraction outcome bar graphs for the ICL and LASIK groups at 6 months postoperatively are given in Figure 11 . The ICL group had signifi cantly more cases within Ϯ0.50 D (91% vs 67%, PϽ.001) and Ϯ1.00 D (99% vs 88%, PϽ.001) of emmetropia than the LASIK group.
DISCUSSION
The most ideal method to compare these refractive techniques would involve conducting both the ICL and LASIK procedures under one randomized, prospective protocol. In this report, ICL cases from a US clinical trial were compared to prospectively collected LASIK cases from one medical center. Despite the prospective nature of the data collection in the LASIK series, the quality of data collected from the ICL US prospective clinical trial is probably more precise, complete, and reliable than that of the LASIK case-control series, with the ICL testing procedures and data collection being performed under a strict standardized protocol in contrast to the usual testing techniques in clinical practice. In addition, although this study was case-matched for certain variables, other factors as yet unknown can notably affect patient outcome, highlighting the importance of using the same comprehensive inclusion/exclusion criteria for both groups as well as randomization of the refractive treatment technique to minimize selection bias. A randomized prospective study design would provide a more precise comparison, yet a large case-control study of the ICL and LASIK series was well matched for key variables of preoperative MRSE, age, and gender, and a randomized trial may be impractical in a real world environment.
The ICL and LASIK outcomes presented in this article were compared to the FDA's target values for safety A B Figure 9 . Comparison of 6-month postoperative defocus equivalent refraction outcomes in the LASIK and ICL series.
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and effi cacy (Table 2 ) as set forth in the "US Refractive Implants Guidance for Investigational Device Exemptions (2000)" and the "Checklist of Information Usually Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers (96)." All of the reported ICL outcomes from the US Visian ICL study and LASIK outcomes from our series were better than the safety and effi cacy FDA target values for preoperative myopia (MRSE) р7.00 D and thus both procedures appear to be safe and effi cacious for this level of myopia through 6-month postoperative follow-up.
In earlier publications, the authors presented two comparative analyses between the ICL and LASIK series, the fi rst in the treatment of moderate to high myopia (Ϫ8.00 to Ϫ12.00 D) 3 followed by an analysis in a lower myopia patient series (Ϫ4.00 to Ϫ7.88 D). 4 In the moderate to high myopia population, every index of BSCVA/UCVA, predictability of refraction, and stability of refraction studied favored the ICL over the LASIK procedure in this range of correction. 3 In the low myopia evaluation, BSCVA of у2 lines, the distribution of change in BSCVA, the proportion of eyes seeing 20/15 and 20/20 uncorrected, the proportion of eyes with predictability (within Ϯ0.50 and Ϯ1.00 D), and the stability of refraction (Ϯ0.50 and Ϯ1.00 D change between 1 and 6 months) were all signifi cantly better with the ICL compared to LASIK. 4 In the two aforementioned comparative articles, no attempt was made to match the ICL and LASIK patient series beyond the range of preoperative myopia, and in A B Figure 11 . Six-month postoperative spherical equivalent manifest refraction graphs for the Implantable Collamer Lens (ICL) and LASIK series.
both the moderate to high and low myopia analyses, the mean preoperative level of myopia was higher in the ICL study cohort. In the current series, the populations were well matched for preoperative spherical equivalent refraction, age, and gender. Myopia as low as 3.00 D was treated in both groups whereas in the previous low myopia comparison no patients were treated with Ͻ4.00 D of myopia.
The results in this current series were similar to the previously reported low myopia series 4 with the same parameters being statistically signifi cantly better in the ICL group. In the previous series, all LASIK procedures were performed with the VISX S2 software and in this series all were performed with the VISX S3 software. The LASIK series reported here represented the current state of the art in LASIK surgical technique, laser/ microkeratome equipment, and operative parameters during the dates of the study. During the time frames of these studies, wavefront-guided ablation (VISX STAR S4 CustomVue 6, 7 and Alcon Laboratories Inc LADARVision4000 CustomCornea 8 excimer laser systems) and other subsequent improvements had not been approved and were not used as a comparison group but would provide a suitable comparator group for future studies. A randomized prospective trial of wavefrontguided ablation versus the use of the ICL is planned for early 2007.
The rate of complications in the LASIK series seems somewhat high; however, the visual results in these cases with complications were good, indicating that the complications were mild in nature. A signifi cant visual loss (2 line loss of BSCVA) due to a complication occurred in only 1 (0.6%) of 164 LASIK cases in this series, 1 case had fi nal BSCVA of 20/30, 1 case was 20/25, and the remainder were у20/20. Furthermore, as shown in Table 2 , this series surpassed all suggested FDA safety and effectiveness targets for laser refractive procedures so it appears to be at least visually representative of outcomes expected with LASIK.
A search of the literature was performed to obtain other LASIK studies with similar time frames, preoperative myopia, and/or laser software as used in the present LASIK group. The clinical outcomes of these published LASIK cases are listed in Table 3 . The rate of complications is less in many of these studies [9] [10] [11] [12] [13] [14] [15] [16] [17] compared to the present LASIK group, which includes 6.7% DLK, 1.8% striae, and 0.6% ectasia, although it should be noted that many of the comparable studies had relatively small patient populations.
The typical incidence of DLK, striae, and ectasia after LASIK was also investigated. A review of the peerreviewed literature found the rate of DLK after LASIK to range from 0.4% to 29%. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The largest investigation was by Stulting et al, 21 who reported an incidence of 0.4% DLK from 15,119 LASIK cases from 1995 to 2002. Another large retrospective study of 2711 LASIK eyes found an incidence of 1.3% developing DLK, including mild DLK cases. 18 Hoffman et al 19 reported 4% with DLK, with 0.7% progressing to grade 3 DLK, from 1000 consecutive LASIK cases.
A single-center study of 980 consecutive LASIK cases found an incidence of 5.3% DLK, yet this rate reduced after modifi cation to their sterilization techniques. 25 Yuhan et al 24 also reported an incidence of 11% DLK in 92 LASIK cases; however, with an alteration in cleaning procedures and fl uids the rate dropped to 2%. The largest incidence was reported by Levinger et al 27 in which 7 (29%) of 24 eyes had grade I to II DLK. It was found that after wiping new microkeratome blades with 100% alcohol the DLK incidence decreased.
The etiology of the 6.7% DLK incidence in the pres- Another search of the peer-reviewed literature reported the incidence of fl ap striae after LASIK to range from 1.1% to 3.5%. [28] [29] [30] [31] [32] The variety of causes of fl ap striae include misalignment of the corneal fl ap after 
fl ap replacement, fl ap desiccation and contraction during laser ablation, fl ap wrinkling during stretching, movement of the corneal fl ap on the fi rst postoperative day, or the tenting effect of the corneal fl ap over the ablated stromal bed. 33 The present LASIK series had three (1.8%) eyes with striae, yet all cases resolved quickly. Striae are relatively uncommon; nevertheless, careful fl ap handling and positioning can prevent many striae.
Review of the LASIK literature for ectasia incidence was also performed. Many of the studies had small to medium patient populations (from 15 to 300 LASIK cases) with no report of ectasia, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] although the study with the largest patient population of 2873 LASIK cases reported an ectasia incidence of 0.66% (19 cases). 44 The present LASIK group reported 1 (0.6%) case with ectasia. Ectasia has no single etiology, and cases with no apparent risk factors have been found to develop ectasia. To minimize ectasia incidence, careful screening of patients should exclude those with preexisting keratoconus/forme fruste keratoconus, abnormal topography, and thin corneas.
The improvement in predictability of the ICL at 6 months over the LASIK procedure (LASIK: 67% Ϯ0.50 D and 88% Ϯ1.00 D compared to ICL: 85% Ϯ0.50 D and 97% Ϯ1.00 D) is not unexpected as it is more accurate to manufacture the exact correction required in a HEMA material than to ablate the correction onto corneal tissue, which is then subject to tissue healing. The improvement in predictability is especially dramatic in view of the fact that 9.1% of the LASIK cases required enhancement surgery within the fi rst 6 months postoperatively compared to none of the ICL cases and astigmatism was treated routinely in the LASIK cases, whereas only spherical correction was attempted with the ICL. Similarly, a more rapid stability of refractive outcome would be expected with the ICL compared to a LASIK procedure because the 3-mm clear corneal incision used in the ICL implantation is known from its use in cataract and IOL surgery to have a minimal effect on refraction 45, 46 whereas corneal refractive changes with LASIK would be expected to take longer to stabilize.
The cases were not matched with regard to preoperative astigmatism. Although signifi cantly less preoperative cylinder was observed in the ICL versus LASIK groups, there was signifi cantly less postoperative cylinder in the LASIK group as cylinder was corrected whereas only spherical correction was attempted in the ICL group. The LASIK group would have been expected to have better postoperative UCVA based on the larger degrees of uncorrected astigmatism in the ICL group; however, postoperative UCVA was better in the ICL group. This could have been a result of the enhanced predictability in the ICL group and/or possibly due to the improved image quality with the ICL versus the LASIK group due to less postoperative higher order aberrations. 47 It should be mentioned that data collected as part of routine follow-up as seen in the LASIK group may not have been encouraged to read the maximum lines of 
UCVA or BSCVA as is usually mandated in a clinical study. This is a well-known study effect, especially at the higher visual acuity levels such as 20/20 and 20/15. Interestingly, the same trends in improved UCVA in the Visian ICL group were also seen at the 20/40 level. The effi cacy outcomes of similar LASIK series (ie, comparable time frames, preoperative myopia, and/or laser software to the current LASIK group) are listed in Table 3 and compared to the Visian ICL results. Three studies used the same laser software as the present LASIK group (VISX Star S3) and were treated for low to moderate myopia. [9] [10] [11] Twa et al 9 performed LASIK on 30 eyes for Ϫ2.00 to Ϫ6.00 D of myopia. When comparing the results to the present ICL group, the preservation and improvement of BSCVA was much better in the ICL series, although UCVA and predictability of refraction were comparable to the ICL results. Seward et al 10 used similar techniques on 49 eyes; the improvement in BSCVA did not compare to that of the ICL group (0% vs 44%; improvement у1 line), yet the ICL vs LASIK/Sanders predictability and stability of refraction were comparable to the ICL series (88% vs 85% and 96% vs 93%, respectively). Finally, Giaconi et al 11 performed LASIK for the treatment of Ϫ1.75 to Ϫ11.00 D of myopia (Ϫ4.74Ϯ2.24 D MRSE); the results were comparable to the ICL series in regards to uncorrected vision, yet the ICL group showed better predictability (Ϯ0.50 D, 76.6% vs 85%).
Several other studies [9] [10] [11] [12] [13] [14] [15] [16] [17] are also presented in Table  3 with similar preoperative myopia and/or surgical time frames as in the present LASIK group; however, different laser systems were used.
Of all the reports, Lin and Tsai 16 showed the most similar preoperative MRSE (Ϫ5.36Ϯ0.67 D vs Ϫ6.01Ϯ1.33 D) and with a similar time frame. Comparison of the 98 LASIK cases to the ICL group showed that preservation of BSCVA and achieved UCVA were comparable; however, the ICL had better predictability of refraction (Ϯ0.50 D: 85% vs 71%; Ϯ1.00 D: 97% vs 91%). 
In reviewing the LASIK literature, it is diffi cult to compare studies to the present ICL and LASIK groups because of the variation in the range of preoperative myopia, laser/software systems, the time frame of the study, and incomplete clinical information. The value of case-matching the ICL and LASIK populations for a more precise comparison is important.
In summary, this matched population comparison of LASIK and ICL cases demonstrated that the ICL performed better than LASIK in almost all measures of safety, effi cacy, predictability, and stability of refraction, supporting the ICL as an effective alternative to standard LASIK for the range of myopia studied. Although this large case-control study produced signifi cant results, further investigation may include a prospective, randomized study design to optimize the accuracy of the comparison between these two refractive surgery techniques.
